Clinical trials of vibegron were conducted in patients with an overactive bladder, the majority of whom were Caucasian (78%) and female (85%) with a mean age of 60 years (range 18 to 93 years).
- TRADE NAME: Gemtesa (Urovant)
- INDICATIONS:
Treatment of an overactive bladder
- CLASS: Beta-3 adrenergic agonist
- HALF-LIFE: approximately 31 hours
- FDA APPROVAL DATE: 12/23/2020
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Digoxin - PREGNANCY: No available data to evaluate drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
